NSE ScannerMedical Devices & Supplies · Medical Specialties · NSE: NURECA · data 2026-11-01
Nureca Ltd.
In plain words
Price: 21.9% below its 52-week high of ₹376.
Delivery: 60.0% of traded shares were kept for delivery over the last 10 sessions, against 57.1% over the last 60.
Latest results: a net profit of ₹4 cr for the quarter ended Sept 2026 (+11.6% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹174 cr |
| Net profit (last 12 months) | ₹5 cr |
| Sales growth, 3 years (yearly) | 9.7% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 70.7% (+5.7 pts in a year), pledged 0.0%, institutions 0.5%.
P/E 61.1, P/B 1.5, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 1.1%, ROCE 3.4%, operating margin 7.0%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth — and sales growth 9.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Promoters raised their holding by 5.7 points in a year.
- Low return on equity (1.1%).
- Expensive on earnings (P/E 61.1).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
NURECA Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹58.53 crore, up 55.1% YoY and up 45.1% QoQ.
Net profit was ₹4.05 crore, up 11.6% YoY and up 31.9% QoQ.
Operating margin was 8.9% (8.7% a year ago).
EPS was ₹4.25, up 17.1% YoY and up 32.4% QoQ.
NURECA के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹58.53 करोड़; पिछले साल की तुलना में 55.1% की बढ़त, पिछली तिमाही की तुलना में 45.1% की बढ़त।
शुद्ध मुनाफ़ा: ₹4.05 करोड़; पिछले साल की तुलना में 11.6% की बढ़त, पिछली तिमाही की तुलना में 31.9% की बढ़त।
ऑपरेटिंग मार्जिन: 8.9% (एक साल पहले 8.7%)।
EPS: ₹4.25; पिछले साल की तुलना में 17.1% की बढ़त, पिछली तिमाही की तुलना में 32.4% की बढ़त।
NURECAના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹58.53 કરોડ; ગયા વર્ષની સરખામણીએ 55.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 45.1% વધારો.
ચોખ્ખો નફો: ₹4.05 કરોડ; ગયા વર્ષની સરખામણીએ 11.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 31.9% વધારો.
ઓપરેટિંગ માર્જિન: 8.9% (એક વર્ષ પહેલાં 8.7%).
EPS: ₹4.25; ગયા વર્ષની સરખામણીએ 17.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 32.4% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results
- 24 Sept 26Insider SAST disclosure: Saurabh Goyal +1 acquired 1,96,993 shares +4.7% next session
- 21 Jul 26Results Q1 FY27 results: profit +279.0% YoY +10.2% next session
- 29 May 26Results Q4 FY26 results: turned to loss vs a year ago -11.8% next session
- 17 Jan 26Results Q3 FY26 results: turned to profit vs a year ago +4.8% next session
- 5 Jan 26Results Q2 FY26 results: turned to profit vs a year ago -2.0% next session
- 15 Jul 25Results Q1 FY26 results: profit −51.2% YoY -9.5% next session
- 7 May 25Results Q4 FY25 results: turned to profit vs a year ago +4.0% next session
- 24 Jan 25Results Q3 FY25 results: turned to loss vs a year ago -9.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹59 cr | ₹4 cr | +11.6% | 8.9% | 4.25 |
| Jun 2026 | ₹40 cr | ₹3 cr | +279.0% | 8.5% | 3.21 |
| Mar 2026 | ₹35 cr | ₹-6 cr | -346.6% | -16.3% | -6.45 |
| Dec 2025 | ₹40 cr | ₹4 cr | — | 8.2% | 3.91 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 70.68% | 68.09% | 68.09% | 64.97% |
| Foreign institutions (FII) | 0.22% | 0.11% | 0.28% | 0.08% |
| Domestic institutions (DII) | 0.24% | 0.24% | 0.24% | 0.04% |
| Mutual funds | 0.00% | 0.00% | — | 0.00% |
| Retail investors | 24.80% | 28.33% | 28.10% | 27.43% |
| Number of shareholders | 31,719 | 33,979 | 34,558 | 35,801 |
Common questions
What was Nureca Ltd.'s latest quarterly profit?
Nureca Ltd. reported a net profit of ₹4 cr for the quarter ended Sept 2026 (+11.6% on the same quarter a year earlier), on revenue of ₹59 cr.
How much do promoters hold in Nureca Ltd.?
Promoters held 70.68% of Nureca Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Nureca Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Nureca Ltd.'s P/E ratio?
About 61.1, based on the last 12 months' earnings and a price of ₹293.8 (data 2026-11-01).
What is the 52-week high and low of Nureca Ltd.?
The 52-week high is ₹376 and the 52-week low is ₹204.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Nureca Ltd. | ₹293.8 | ₹285 cr | 61.1 | 1.5 | 1.1% | 3.4% | 0.01 | +13.0% |
| Q-Line Biotech Limited | ₹512.75 | ₹1,196 cr | — | — | 25.6% | 27.9% | 0.92 | +13.4% |
| MIC Electronics Limited | ₹35.41 | ₹1,057 cr | — | — | -5.8% | 9.4% | 0.2 | -35.6% |
| Osel Devices Limited | ₹335.5 | ₹541 cr | 29 | — | 19.6% | 34.3% | 0.49 | -45.3% |
| Yash Optics and Lens Limited | ₹118.05 | ₹292 cr | 32.3 | 2.9 | 9.5% | 11.6% | 0.05 | -9.2% |
| Avience Biomedicals Limited | ₹253.15 | ₹139 cr | 11.7 | 3.3 | 32.4% | 35.9% | 0.92 | -35.9% |
Compare NURECA with QLINE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NURECA in NSE Scanner →